Coherus BioSciences Announces New Employment Inducement Grants
June 22 2018 - 8:00AM
Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that
effective June 21, 2018, the compensation committee of the
company’s board of directors granted 8 new employees options to
purchase an aggregate of 142,000 shares of the company’s common
stock with a per share exercise price of $16.30, the closing
trading price on the grant date. The stock options were
granted pursuant to the Coherus BioSciences, Inc. 2016 Employment
Commencement Incentive Plan, which was approved by the company’s
board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq
Global Select Market for equity grants to induce new employees to
enter into employment with the company.
About Coherus BioSciences, Inc.Coherus is a
U.S. based integrated development and commercialization biologics
company, focused on biosimilars. Biosimilars are intended for
use in place of existing, branded biologics to treat a range of
chronic and often life-threatening diseases, with the potential to
reduce costs and expand patient access. Our team is composed of
industry veterans with expertise in process science, analytical
characterization, protein production, sales & marketing and
clinical-regulatory development. Coherus is advancing CHS-1701
(pegfilgrastim biosimilar) towards commercialization, and has
completed Phase 3 clinical programs for two anti-TNF product
candidates, CHS-1420 (adalimumab biosimilar) and CHS-0214
(etanercept biosimilar). Coherus is also developing an early stage
pipeline of ophthalmology biosimilar product candidates.
CONTACT:Jean-Frédéric ViretChief Financial OfficerCoherus
BioSciences, Inc.jviret@coherus.com+1 (650)
649-3546
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024